SCHEMBL24449243

SCHEMBL24449243

CN1CCC(Cc2ccc(NC(=O)Nc3cc(-c4ccc(-c5ccc(N)nc5)cc4)n(C)n3)cc2C(F)(F)F)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 11/20 0.56
▸ ABL2 P42684 6/20 0.56
▸ NTRK1 P04629 1/20 0.49
▸ NTRK3 Q16288 1/20 0.49
▸ NTRK2 Q16620 1/20 0.49
▸ FGFR4 P22455 4/20 0.49
▸ RET P07949 4/20 0.48
▸ KDR P35968 3/20 0.48
▸ MAPK14 Q16539 3/20 0.44
▸ MKNK1 Q9BUB5 4/20 0.42
▸ MKNK2 Q9HBH9 4/20 0.42
▸ BCR P11274 4/20 0.42
▸ KIT P10721 3/20 0.42
▸ PDGFRB P09619 2/20 0.42
▸ PDGFRA P16234 2/20 0.42
▸ FGFR2 P21802 2/20 0.42
▸ FLT3 P36888 2/20 0.42
▸ EIF4E P06730 1/20 0.42
▸ CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29614857 0.89 ABL1 (0.51) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL19307090 0.89 ABL1 (0.51) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL19316705 0.88 ABL1 (0.71) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL24448260 0.85 ABL1 (0.73) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL24449085 0.78 ABL1 (0.62) ABL1ABL2FGFR4RETKDR
SCHEMBL29614931 0.77 ABL1 (0.65) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL19307164 0.77 ABL1 (0.65) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL24449267 0.76 ABL1 (0.61) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL24448254 0.76 ABL1 (0.70) ABL1ABL2NTRK1NTRK3NTRK2
SCHEMBL12973423 0.75 ABL1 (0.50) ABL1ABL2FGFR4RETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES CORNELL UNIVERSITY 2022-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES PTGES, PTGS1, PTGES2 ABL1 4516/4885ABL2 2755/4885NTRK1 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback